Members of our team had the opportunity to present a new poster abstract at the 2023 NASP Annual Meeting & Expo, which was held from September 18-21.
Background
- Clinical pharmacists are equipped with the knowledge and skills to standardize the patient care process and optimize patient outcomes within hemophilia treatment centers.
- The National Hemophilia Foundation’s Medical and Scientific Advisory Council recommends Hemlibra® (emicizumab kxwh) as a first-line agent for any persons with hemophilia A who have spontaneous or traumatic bleeding episodes.
- Addition of a clinical pharmacist to a hemophilia treatment team improved health care-related outcomes and drug-related costs.
- TherigySTM is a clinical care management and reporting technology platform that
empowers pharmacy staff to optimize workflow, improve patient adherence, streamline operational efficiencies, and drive growth.
Objectives
To evaluate the impact of a hemophilia A patient care management program (PCMP) on clinical outcomes, patient-reported outcomes, medication adherence, and pharmacist interventions in patients prescribed emicizumab-kxwh utilizing TherigySTM, a clinical care management and reporting technology platform.
Read about the team's findings by downloading the Outcomes Study below.
Download the abstract: